We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Gene-Based Risk Scores Predicts Alcoholic Cirrhosis

By LabMedica International staff writers
Posted on 23 Jan 2019
Alcoholic chronic liver disease, with a prevalence of around 12% in the European and North-American populations, is characterized by a broad spectrum of conditions ranging from simple steatosis to alcoholic steatohepatitis, cirrhosis, and hepatocellular carcinoma.

Environmental factors, aging, genetic predisposition, and gender play a pivotal role in alcoholic cirrhosis development and progression. More...
The most established environmental factors influencing the susceptibility to chronic alcohol-related liver damage are represented by dose and pattern of alcohol intake, diet, obesity, diabetes, and smoking.

An international team of clinical and molecular scientists working with The Sahlgrenska Academy (Göteborg, Sweden) retrospectively examined a total of 416 male at-risk alcohol drinkers. The possible presence of cirrhosis was also assessed and the time of cirrhosis diagnosis was reported using data from hospital discharge papers, medical records, physical examination, blood tests, imaging, and endoscopy.

Buffy coat fraction was recovered from whole blood EDTA and DNA extraction was performed using QIAamp DNA Blood Kit. PNPLA3 rs738409, CD14 rs2569190, TM6SF2 rs58542926, and MBOAT7 rs641738 variants were genotyped by TaqMan genotyping assay. Post-polymerase chain reaction (PCR) allelic discrimination was performed on a CFX384 Real-Time System by measuring allele-specific fluorescence.

The team reported that PNPLA3, CD14, and TM6SF2 were associated with alcoholic cirrhosis prevalence. PNPLA3 and CD14 were also associated with its incidence. A threshold of 7.27 was identified as cutoff for the predictive risk of alcoholic cirrhosis development in 36 years from the onset of at-risk alcohol consumption with 70.1% sensitivity and 78.7% specificity. The negative predictive value and the positive predictive value were 90.2% and 48.6%, respectively.

The authors concluded that identifying genetic and environmental candidate factors that confer susceptibility to alcoholic cirrhosis development could potentially inform the clinician on patient management. It would be useful, for clinicians, to predict, since the first visit, the risk over time of alcoholic cirrhosis in male patients with at-risk alcohol consumption and to select a population with a high risk to develop cirrhosis in order to plan a patient-tailored therapy. The study was published on January 10, 2019, in the journal The Application of Clinical Genetics.

Related Links:
The Sahlgrenska Academy


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.